Episodes

1d ago

In this episode, we explore brexanolone and zuranolone—the first FDA-approved medications specifically for postpartum depression. How do these neurosteroid-based treatments work differently than traditional antidepressants, and could they offer relief in just days rather than weeks? Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding Postpartum Mood Disorders: A Comprehensive Guide The Role of Brexanolone and Zuranolone in Postpartum Depression

6d ago

In this episode, we explore lumateperone for treating major depressive episodes with mixed features – that challenging presentation where patients experience depression alongside racing thoughts and restlessness. Can we effectively treat both the despair and the activation without triggering mania? Dr. Kristin Raj examines the evidence and clinical implications for this understudied population. Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 76 Lumateperone for Depression with Mixed Features: Is It Effective?

Dec 12

In this episode, we explore pharmacologic treatment for postpartum depression in breastfeeding mothers. Can psychiatric medications be safely used while nursing? Dr. Lauren Osborne explains how nearly all antidepressants are compatible with breastfeeding, why postpartum women may respond faster to treatment, and how to choose the right medication. Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding Postpartum Mood Disorders: A Comprehensive Guide Postpartum Depression: Pharmacologic Considerations for Breastfeeding Mothers

Dec 7

In this episode, we explore a new study examining whether antidepressants and antipsychotics truly increase the risk of torsades de pointes, a potentially fatal cardiac arrhythmia. What does the evidence say about using multiple psychiatric medications together, and when should we actually be concerned? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 75 Torsades de Pointes: Impact of Antidepressants and Antipsychotics

Dec 2

In this episode, we explore the critical distinction between postpartum OCD and postpartum psychosis. Dr. Lauren Osborne reveals why accurate diagnosis matters for treatment and safety. Did you know intrusive thoughts about infant harm don't actually indicate elevated risk in OCD, but do in psychosis? Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding Postpartum Mood Disorders: A Comprehensive Guide Distinguishing Postpartum OCD from Postpartum Psychosis

Nov 27

In this episode, we examine groundbreaking research that challenges the widespread clinical belief that SSRI side effects improve with time. Using data from the landmark STAR*D trial, we explore which patients actually experience side effect resolution and which face worsening symptoms. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 75 Do SSRI Side Effects Improve Over Time?

Nov 22

In this episode, we explore evidence-based strategies for augmenting lithium when monotherapy fails in acute mania. Why is quetiapine the preferred add-on to valproate, despite decades of clinical tradition favoring anticonvulsants? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: An Update on Bipolar Mania Algorithm Augmenting With SGAs After Unsatisfactory Response to Lithium in Bipolar Mania

Nov 17

In this episode, we explore a groundbreaking Mayo Clinic algorithm that revolutionizes antipsychotic selection for first-episode psychosis. Should the presence of violence completely change your medication choice strategy? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 75 Schizophrenia Algorithm: Selecting an Antipsychotic for First Episodes

Nov 12

In this episode, we challenge conventional prescribing by exploring why lithium should be the first-line treatment for acute classic mania, despite widespread use of antipsychotics. Dr. David Osser presents evidence-based arguments for lithium's unique neuroprotective benefits and long-term efficacy. Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: An Update on Bipolar Mania Algorithm Lithium for Bipolar Mania Without Mixed Features

Nov 7

In this episode, we explore a head-to-head comparison of trazodone, doxepin, and melatonin for treating insomnia when benzodiazepines are off the table. Which non-benzodiazepine sleep aid offers the best balance of effectiveness and tolerability in real-world psychiatric patients? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Melatonin, Trazodone, or Doxepin for Sleep Disorders

Nov 2

In this episode, we explore the critical decision of when to add lithium or valproate to second-generation antipsychotics in mixed manic episodes. Should you rush to combination therapy under managed care pressure, or does patience with strategic benzodiazepine bridging lead to better outcomes? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: An Update on Bipolar Mania Algorithm Choosing Between Valproate or Lithium Augmentation for Bipolar Mania With Mixed Features

Oct 28

In this episode, we explore a provocative argument for reconsidering disulfiram as a first-line treatment for alcohol use disorder. Could this decades-old medication, often dismissed as outdated and dangerous, actually be more effective than newer alternatives when used in appropriately selected patients? Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Alcohol Use Disorder: Should Disulfiram Be First-Line?

Oct 23

In this episode, we explore the complex pharmacological management of mixed mania, a challenging bipolar presentation affecting up to 40% of manic episodes. Why do traditional mood stabilizers like lithium fall short, and which second-generation antipsychotics emerge as first-line treatments for this dual-symptom condition? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: Lithium: How to Manage Dosage and Side Effects Managing Renal Side Effects of Lithium Therapy

Oct 18

In this episode, we explore psychedelic-assisted therapy in clinical practice, examining how these treatments differ fundamentally from traditional pharmacotherapy. Can psychiatrists reconcile mystical experiences with evidence-based medicine while navigating the complex therapeutic paradigm of preparation, 8-hour sessions, and integration work? Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: Use of Psychedelic Drugs in Psychiatry Psychedelic-Assisted Therapy in Clinical Practice

Oct 13

In this episode, we explore groundbreaking research revealing that lower doses of lurasidone (40-60mg) may be more effective for bipolar depression than higher doses. Could we be over-medicating our patients when the sweet spot for both efficacy and tolerability lies in this unexpected lower range? Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Lurasidone for Bipolar Depression: What Is the Optimal Dose?

Oct 8

In this episode, we explore a compelling comparison between olanzapine and risperidone for managing behavioral symptoms in dementia patients. Are the delusions we see in Alzheimer's disease actually true delusions, or something entirely different that requires a new treatment approach? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 73 Alzheimer's Disease: Olanzapine vs. Risperidone for BPSD

Oct 3

In this episode, we explore the complex drug-drug interactions between psychedelics and psychiatric medications. Do SSRIs really blunt psychedelic effects, or is this just clinical folklore? We'll examine surprising new research and discuss potentially dangerous combinations every psychiatrist should know. Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Use of Psychedelic Drugs in Psychiatry Examining the Combined Use of Psychedelics and Psychiatric Drugs

Sep 28

In this episode, we challenge the conventional wisdom of "what gets them well keeps them well" by exploring groundbreaking Finnish research on bipolar disorder medication dosing. Does maintaining patients on high doses actually improve long-term outcomes, or could standard doses be the optimal strategy for relapse prevention? Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Quick Take Vol. 73 Bipolar Disorder Maintenance: What's the Optimal Dose Range?

Sep 23

In this episode, we explore how psychedelics like psilocybin disrupt the brain's default mode network, creating windows of neuroplasticity that correlate with mystical experiences and therapeutic breakthroughs in treatment-resistant depression, anxiety, and addiction. Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 1.25 CMEs: Use of Psychedelic Drugs in Psychiatry How Psychedelics Influence Brain Networks

Sep 18

In this episode, we explore groundbreaking research showing how long-acting injectable antipsychotics can literally save lives in schizophrenia treatment. Could choosing the right medication delivery method be the difference between a patient thriving or facing premature death by 15-20 years? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Quick Take Vol. 73 Long-Acting Injectables: Superior for Reducing Mortality in Schizophrenia?

Sep 13

In this episode, we explore the fascinating mechanisms behind psychedelic drugs in psychiatry, examining how substances like psilocybin and LSD work through 5-HT2A receptors to promote neuroplasticity. What if these compounds are hijacking an ancient stress response system designed to help us rapidly adapt to survive? Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Use of Psychedelic Drugs in Psychiatry The Mechanisms and Effects of Psychedelics

Sep 8

In this episode, we explore groundbreaking research comparing weight gain across eight common antidepressants. Using data from 183,000 patients, this study finally provides concrete numbers to answer the question patients ask most: How much weight will I gain on this medication? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 72 Which Antidepressants Cause the Most Weight Gain?

Sep 3

In this episode, we explore lisdexamfetamine as the first FDA-approved medication for binge eating disorder. Can one medication effectively treat both ADHD and binge eating simultaneously? We examine the evidence, duration of treatment, and strategies for addressing patient ambivalence in eating disorder pharmacotherapy. Faculty: Scott Crow, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Binge Eating Disorder Pharmacotherapy: Lisdexamfetamine

Aug 29

In this episode, we explore groundbreaking Swedish research on GLP-1 receptor agonists as a potential new treatment for alcohol use disorder. Could diabetes medications like semaglutide revolutionize addiction treatment where traditional therapies have fallen short? Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 72 Which Antidepressants Cause the Most Weight Gain?

Aug 24

In this episode, we explore pharmacotherapy for binge eating disorder, examining how antidepressants, anticonvulsants, and emerging treatments target different patient goals. Should your treatment focus on stopping binge episodes or achieving weight loss? We discuss evidence-based approaches to align medication choices with patient priorities for optimal outcomes. Faculty: Scott Crow, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Binge Eating Disorder Pharmacotherapy: Antidepressants and Anticonvulsants

Aug 19

In this episode, we explore the confusing world of lithium therapeutic levels with Dr. Paul Zarkowski. Why do different labs recommend different ranges for the same medication? We examine expert consensus on optimal dosing strategies for both acute treatment and maintenance therapy in bipolar disorder. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 What is the Optimal Therapeutic Range for Lithium in Bipolar Disorder?

Aug 14

In this episode, we explore evidence-based pharmacotherapy for bulimia nervosa, including why higher doses of SSRIs work better than standard dosing, which medications to avoid completely, and how antidepressants can be effective even without depression being present. Why does fluoxetine require 60 mg daily for optimal results? Faculty: Scott Crow M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Pharmacotherapy of Eating Disorders: An Update Bulimia Nervosa: Medications That Work

Aug 9

In this episode, we explore groundbreaking research on managing antipsychotic-induced weight gain through a comprehensive network meta-analysis. Could the combination of low-dose metformin and lifestyle modifications be the game-changer that helps patients maintain both mental stability and physical health? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 Antipsychotic-Induced Weight Gain: Best Management Strategies

Aug 4

In this episode, we explore extended-release naltrexone for opioid use disorder, examining its unique role as a pure antagonist in patients who require safety-sensitive careers. How do we successfully navigate the challenging initiation period when patients must be opioid-free for a week? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Examining the Efficacy of Extended-Release Naltrexone OUD

Jul 30

In this episode, we explore the surprising link between antipsychotic medications and pneumonia risk. Did you know that pneumonia is the fourth leading cause of death in schizophrenia patients, and certain medications increase this risk in unexpected ways? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 Pneumonia in Schizophrenia: Which Antipsychotics Pose the Highest Risk for?

Jul 25

In this episode, we explore how to choose between methadone, buprenorphine, and naltrexone for opioid use disorder treatment. With over 100,000 overdose deaths annually, how do we match the right medication to save each patient's life? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Tailored Patient Assessment: A Key to Effective OUD Treatment

Jul 20

In this episode, we explore buprenorphine management for opioid use disorder, covering induction protocols, dosing strategies, and long-term maintenance. Why do patients need to be in withdrawal before starting this life-saving medication, and how can we make this challenging process more manageable? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Buprenorphine for Managing OUD

Jul 15

In this episode, we explore groundbreaking research on valproate's dose-dependent weight gain effects. Could prescribing lower doses be the key to maintaining therapeutic benefits while minimizing one of psychiatry's most challenging side effects? Dr. Paul Zarkowski reveals surprising findings that could transform your valproate prescribing approach. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 70 Is Valproate Weight Gain Dose-Dependent?

Jul 10

In this episode, we explore methadone maintenance therapy for opioid use disorder, covering dosing strategies, recent regulatory changes, and safety considerations. Why do so many patients fail on methadone despite its proven effectiveness, and how can proper dosing make the difference between recovery and relapse? Faculty: Smita Das, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Pharmacologic Management of Opioid Use Disorder Methadone for Managing OUD

Jul 5

In this episode, we explore the puzzling connection between clozapine and obsessive-compulsive symptoms in schizophrenia patients. Does this wonder drug actually cause OCD, or are we missing a deeper story about how protective behaviors transform into compulsive habits? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 70 Clozapine and OCD-Like Symptoms: What's the Connection?

Jun 30

In this episode, we explore groundbreaking head-to-head research comparing topiramate and naltrexone for alcohol use disorder, revealing surprising equivalence in effectiveness. Could the off-label option actually be as good as our FDA-approved standard for treating problematic drinking? Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 69 Can Topiramate Replace FDA-Approved Medications for Alcohol Use Disorder?

Jun 25

In this episode, we discuss the critical challenges of benzodiazepine discontinuation, exploring Benzodiazepine-Induced Neurological Dysfunction (BIND) and effective support strategies for patients experiencing protracted withdrawal. What can clinicians do when over 50% of patients report finding more help from online forums than from medical professionals? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Strategies for Successful Benzodiazepine Deprescribing Beyond Benzodiazepine Discontinuation: Understanding Life Effects and Support Strategies

Jun 20

In this episode, we explore the potentially fatal side effects of clozapine that often receive less attention than agranulocytosis: bowel obstruction and pneumonia. Could your vigilant monitoring of blood counts be overshadowing equally dangerous risks? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 69 Clozapine: The Hidden Risks of Ileus and Pneumonia

Jun 15

In this episode, we discuss evidence-based strategies for safely tapering patients off benzodiazepines, including cut-and-hold and microtapering techniques. What's the best approach when commercial dosage forms limit gradual reductions? Faculty: Alexis Ritvo Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Strategies for Successful Benzodiazepine Deprescribing Techniques for Successful Benzodiazepine Tapering

Jun 10

In this episode, we explore lithium's surprising positive effect on bone mineral density in patients with bipolar disorder. Could the medication many psychiatrists use as a mood stabilizer also be protecting patients from osteoporosis? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 68 Can Lithium Protect Against Osteoporosis?

Jun 5

In this episode, we explore evidence-based strategies for successful benzodiazepine tapering with addiction psychiatrist Dr. Alexis Ritvo. How can clinicians minimize withdrawal effects while supporting patients through this challenging process? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 1.25 CMEs: Strategies for Successful Benzodiazepine Deprescribing Understanding the Principles of Benzodiazepine Tapering

May 31

In this episode, we explore compelling evidence from the UK Biobank showing how vitamin D deficiency may increase dementia risk by up to 25%. Could this affordable supplement be an essential piece of your brain health strategy? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 68 Can Vitamin D Deficiency Increase the Risk of Alzheimer's Disease?

May 26

In this episode, we explore the complex process of benzodiazepine deprescribing, examining when and how to help patients reduce or discontinue these medications. How can clinicians balance the benefits of deprescription against the challenges of withdrawal? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: Strategies for Successful Benzodiazepine Deprescribing Benzodiazepine Deprescription: Indications, Benefits, and Risks

May 21

In this episode, we explore the unique considerations for using long-acting injectable antipsychotics in women with schizophrenia. How might hormonal fluctuations throughout a woman's life impact treatment decisions for schizophrenia? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 68 Long-Acting Antipsychotics: An Option for Women with Schizophrenia?

May 16

In this episode, we explore the challenges and current guidelines for benzodiazepine use in pregnancy, breastfeeding, and adolescence. When is it appropriate to continue benzodiazepines during pregnancy, and what alternatives should clinicians consider? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide Consequences of Benzodiazepine Use in Pregnancy, Breastfeeding, and Adolescence

May 11

In this episode, we explore benzodiazepine use disorder, distinguishing between physical dependence and addiction while examining practical strategies for safe prescribing. Did you know only 1.5% of benzodiazepine users actually develop a use disorder? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide Benzodiazepine Use Disorder

May 6

In this episode, we explore the potential role of the probiotic Akkermansia muciniphila in managing olanzapine-induced weight gain. Could this tiny gut bacterium be the key to maintaining metabolic health while on antipsychotics? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 67 Olanzapine-Induced Weight Gain: Can Akkermansia Muciniphila Help?

May 1

In this episode, we explore the dangerous risks of benzodiazepine use, focusing on the potentially lethal combination with opioids, cognitive impairment, increased accident risk, and fall hazards. Did you know that benzodiazepines combined with opioids increase overdose risk fivefold in the first 90 days? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide Understanding the Major Risks of Benzodiazepine Use

Apr 26

In this episode, we explore the latest research on antidepressant discontinuation symptoms, revealing that about 14% of patients experience these effects when stopping medication. Which antidepressants are most likely to cause these "brain zaps" and other withdrawal symptoms? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 67 Which Antidepressants Have the Highest Risk of Discontinuation Symptoms?

Apr 21

In this episode, we discuss the appropriate use of benzodiazepines, focusing on evidence-based indications and optimal medication selection. Did you know that alprazolam has unique properties that make it more addictive than other benzodiazepines? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide Appropriate Benzodiazepine Use: Indications and Optimal Selection

Apr 16

In this episode, we explore the evidence behind Transcranial Magnetic Stimulation (TMS) for depression, from early clinical trials to real-world effectiveness. What makes some patients respond better to TMS than others? We discuss response rates, treatment protocols, and the exciting development of faster treatment options. Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Exploring the Evidence of TMS for Depression

Apr 11

In this episode, we explore the crucial aspects of patient selection for Transcranial Magnetic Stimulation (TMS) in treating depression. We discuss insurance criteria, contraindications, and practical considerations. Did you know that while TMS was FDA-approved in 2008, it wasn't widely accessible until Medicare began covering it in 2014? Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Optimizing Patient Selection for TMS Treatment

Apr 6

In this episode, we explore a landmark Finnish study examining the long-term risk of agranulocytosis in patients taking clozapine. The research followed 62,000 patients over 22 years, providing crucial data about this rare but serious side effect. Could these findings change how we approach clozapine prescribing and monitoring requirements? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 66 Does Clozapine's Agranulocytosis Risk Persist Beyond Initial Treatment Period?

Apr 1

In this episode, we explore Transcranial Magnetic Stimulation (TMS) as a treatment option for Obsessive-Compulsive Disorder (OCD). We discuss the FDA-approved devices, unique protocols, and why patients need their anxiety triggered before each session. Did you know TMS for OCD targets a completely different brain region than TMS for depression? Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Exploring the Evidence of TMS for OCD

Mar 27

In this episode, we explore donanemab, a groundbreaking monoclonal antibody treatment for Alzheimer's disease. We discuss its efficacy in reducing beta-amyloid plaques, unique treatment duration protocol, and safety considerations. Could this time-limited treatment approach revolutionize how we manage Alzheimer's progression? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 66 Can Donanemab Slow Alzheimer's Progression?

Mar 22

In this episode, we explore a groundbreaking Danish registry study that challenges common beliefs about long-term benzodiazepine use and dose escalation patterns. Are our concerns about inevitable tolerance and dependence justified? The study's findings might surprise you and reshape prescribing practices. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 65 Do Benzodiazepine Users Escalate Doses Over Time?

Mar 17

In this episode, we explore the side effects and safety considerations of Transcranial Magnetic Stimulation (TMS) therapy in psychiatry. Did you know that despite common concerns, fewer than 2% of patients discontinue TMS due to discomfort? We'll discuss everything from common side effects to practical management strategies. Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Assessing the Potential Side Effects of TMS

Mar 12

In this episode, we explore the crucial interaction between SSRIs and oral anticoagulants, examining a groundbreaking 23-year study of over 330,000 patients. Does combining these medications significantly increase bleeding risk, and if so, how can we safely manage patients who need both treatments? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 65 Can SSRIs Be Safely Prescribed With Oral Anticoagulants?

Mar 7

In this episode, we explore the safe use and monitoring of lamotrigine, focusing on cardiac risks and when EKG monitoring is necessary. Did you know that reducing lamotrigine dose doesn't actually mitigate cardiac risks but could increase the risk of psychiatric destabilization? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects Strategies for Safe Usage and Proper Monitoring of Lamotrigine

Mar 2

In this episode, we explore the often-overlooked phenomenon of antipsychotic withdrawal, examining new findings from the world's largest drug safety database. Could some cases of apparent psychotic relapse actually be withdrawal symptoms in disguise? We discuss common withdrawal effects, risk factors, and evidence-based strategies for safe medication discontinuation. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 64 Antipsychotic Withdrawal Syndrome: Symptoms, Risks, and Prevention Strategies

Feb 25

In this episode, we explore lamotrigine's cardiac side effects, focusing on QTc prolongation and QRS widening. How concerned should psychiatrists be about the FDA warning regarding lamotrigine's cardiac effects? We examine the evidence behind these concerns and discuss practical implications for clinical practice. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects Lamotrigine Effect on QTc Prolongation and QRS Widening

Feb 20

In this episode, we examine a groundbreaking Danish study that challenges the conventional belief that sedative medications increase fall risk in older adults. Could untreated insomnia, rather than the medications used to treat it, be the real culprit behind falls in elderly patients? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 64 Insomnia in the Elderly: Do Sedatives Increase or Decrease Fall Risk?

Feb 15

In this episode, we explore lamotrigine's side effects and special considerations, particularly focusing on identifying dangerous skin reactions, pregnancy considerations, and overdose risks. Did you know that Asian populations may require special genetic screening before starting lamotrigine due to increased skin reaction risks? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects Lamotrigine: Side Effects and Special Considerations

Feb 10

In this episode, we explore the efficacy and safety of iloperidone in treating bipolar disorder, examining new phase 3 trial data that reveals both promising results for mania symptoms and important considerations about side effects. Can this antipsychotic's favorable EPS profile outweigh its metabolic risks? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 63 Iloperidone: A Potential Treatment Option for Bipolar Mania

Feb 5

In this episode, we explore the vital aspects of prescribing lamotrigine, from its mechanisms to titration schedules. Did you know that birth control pills can cut lamotrigine levels in half within just one week? Understanding these interactions is crucial for safe and effective treatment. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects Understanding Lamotrigine Mechanisms and Titration Schedule

Jan 31

In this episode, we explore the pharmacological management of agitation in emergency settings, focusing on benzodiazepines and the novel medication dexmedetomidine. Did you know there's now a sublingual option that works through an entirely different mechanism than traditional anti-agitation medications? Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies The Role of Benzodiazepines and Dexmedetomidine in Managing Agitation

Jan 26

In this episode, we explore KarXT, a groundbreaking experimental antipsychotic that works through the cholinergic system rather than dopamine pathways. Could this novel approach revolutionize schizophrenia treatment by offering similar efficacy to current antipsychotics but without the motor side effects? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 63 Xanomeline-Trospium (KarXT) Shows Efficacy in Phase 3 Trial for Schizophrenia

Jan 21

In this episode, we explore evidence-based pharmacologic strategies for managing acute agitation in emergency settings, challenging the stigmatizing concept of "chemical restraints" and providing practical approaches to achieve optimal patient outcomes. Did you know that many agitated patients can actively participate in medication decisions, even during a crisis? Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies Pharmacologic Strategies for Managing Agitation: General Recommendations and Treatments Goals

Jan 16

In this episode, we explore how famotidine, a common heartburn medication, might help treat post-COVID brain fog. New research suggests this H2 blocker could improve cognitive function in recovering patients. But how does a stomach acid reducer potentially clear mental haziness? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 62 Famotidine for COVID-19 Brain Fog: A Promising Treatment Option

Jan 11

In this episode, we explore nonpharmacologic strategies for managing agitated patients, focusing on verbal de-escalation techniques. Did you know that using physical restraints adds an average of four hours to an emergency department stay? Dr. Scott Zeller shares evidence-based approaches to transform crisis intervention in emergency settings. Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies Nonpharmacologic Strategies for Managing Agitation: Verbal De-Escalation

Jan 6

In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 62 Antipsychotic Dose Reduction in Schizophrenia: Insights From the RADAR Trial

Jan 1

In this episode, we explore the challenges of diagnosing and managing agitation in emergency settings, focusing on mood disorders and substance use. Dr. Scott Zeller shares insights on differentiating acute mania from substance-induced psychosis. How can clinicians navigate the complex interplay between psychiatric symptoms and substance effects in emergencies? Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies Other Psychiatric Diagnoses in Agitated Patients: Mood and Substance Use Disorders

Dec 27, 2024

In this episode, we explore the use of high-dose olanzapine as a potential alternative to clozapine for treatment-resistant schizophrenia. We discuss a systematic review that examines the efficacy and safety of olanzapine doses above the FDA-approved maximum. Could high-dose olanzapine be a viable option when patients refuse clozapine? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 61 Is High-Dose Olanzapine an Option for Treatment-Resistant Schizophrenia?

Dec 22, 2024

In this episode, we explore how integrating psychodynamic principles into pharmacotherapy can enhance treatment outcomes. We discuss seven key features of psychodynamic psychotherapy and their application in routine psychiatric practice. How might understanding a patient's fantasies about their illness impact their response to medication? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills Psychotherapy Skills in Everyday Practice: Ordinary Medical Psychotherapy

Dec 17, 2024

In this episode, we explore strategies for discontinuing benzodiazepines in hospitalized elderly patients. We discuss a recent Israeli study that tested two interventions during inpatient stays. Can a simple hospital-based intervention lead to successful long-term medication changes? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 61 Stopping Benzodiazepines and Z-Drugs in Hospitalized Elderly Patients

Dec 12, 2024

In this episode, we explore the critical role of therapeutic alliance in psychopharmacology. We discuss how factors like empathy, communication, and shared decision-making can significantly impact treatment outcomes. Did you know that a doctor's warm voice can increase appointment adherence by 162%? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills Pharmacotherapy Alliance, Treatment Preferences, and Communication

Dec 7, 2024

In this episode, we explore the cardiac and metabolic safety profile of antipsychotics in youth, based on a World Health Organization Safety Database analysis. We discuss age-dependent risks, specific medication concerns, and the importance of monitoring. How can clinicians balance the benefits of antipsychotics with potential cardiometabolic risks in young patients? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 20 Cardiac and Metabolic Safety Profile of Antipsychotics in Youth

Dec 2, 2024

In this episode, we explore the unexpected consequences of promoting a purely biological view of mental illness. How does framing mental health conditions as solely biological affect stigma, patient outcomes, and physician empathy? We delve into the complex interplay between biological and psychosocial factors in mental health treatment. Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills The Biological Theory of Illness and Stigma

Nov 27, 2024

In this episode, we explore the bidirectional relationship between psychiatric disorders and cardiovascular disease, discussing a groundbreaking study involving over 900,000 subjects. We ask: Can a mental health diagnosis increase your risk of heart disease? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership her Earn 0.5 CMEs: Quick Take Vol. 60 Psychiatric Disorders and Subsequent Risk of Cardiovascular Disease

Nov 22, 2024

In this episode, we explore the science behind the art of psychopharmacotherapy with Dr. David Mintz. We delve into how psychosocial factors, including the prescriber's approach, can significantly impact medication outcomes. Did you know that some psychiatrists achieve better results with placebos than others do with active medications? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills The Science of the Art of Psychopharmacotherapy

Nov 17, 2024

In this episode, we explore the long-term effects of methylphenidate on sleep in children and adolescents with ADHD. Can stimulant medication actually improve sleep in ADHD patients? We dive into surprising research findings that challenge common assumptions about ADHD treatment and sleep disturbances. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 20 Long-Term Effects of Methylphenidate on Sleep in Children and Adolescents With ADHD

Nov 12, 2024

In this episode, we explore the strategic use of natural medications in psychiatry, focusing on combination therapies for various mental health conditions. Dr. David Mischoulon discusses potential synergies between natural remedies and conventional drugs, as well as all-natural combinations. But how do we balance efficacy with safety when using these less-studied treatments? Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies Potential Combinations of Natural Medication for Psychiatric Disorders

Nov 7, 2024

In this episode, we explore the use of memantine in treating trichotillomania and skin picking disorder. Could this common Alzheimer's medication be the breakthrough we've been waiting for in managing body-focused repetitive behaviors? Dr. Bob Hudak discusses a promising study that offers new hope for patients struggling with these often-overlooked conditions. Faculty: Robert Hudak, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 60 Efficacy of Memantine in Treating Trichotillomania and Skin-Picking Disorder

Nov 2, 2024

In this episode, we explore Ashwagandha, a versatile natural remedy in psychiatry. We discuss its potential applications in treating anxiety, depression, OCD, and other mental health disorders. Could this ancient herb be the key to managing treatment-resistant patients? Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies Ashwagandha (ASW): Potential Indications and Administration in Psychiatric Disorders

Oct 28, 2024

In this episode, we explore the controversial use of electroconvulsive therapy (ECT) in adolescents with severe depression and suicidality. We discuss a study examining ECT's effectiveness, factors influencing outcomes, and its potential as a treatment option. Is ECT a viable last resort for treatment-resistant depression in teens? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 19 Electroconvulsive Therapy for Adolescents With Severe Depression and Suicidality

Oct 23, 2024

In this episode, we explore the potential uses of Cannabidiol (CBD) in psychiatric practice. We discuss its mechanisms, evidence for various disorders, and guidelines for safe use. Is CBD the next breakthrough in mental health treatment, or just another passing trend? Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies Cannabidiol: Evidence for Psychiatric Disorders and Recommendations for Using It

Oct 18, 2024

In this episode, we explore the use of medical cannabis in treating Parkinson's disease. We discuss a retrospective study that reveals promising results for both motor and non-motor symptoms. Could medical cannabis be the versatile solution we've been seeking for Parkinson's treatment? Faculty: Gregory Pontone, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 59 Medical Cannabis in the Treatment of Parkinson's Disease

Oct 13, 2024

In this episode, we explore the potential of N-acetylcysteine (NAC) in treating mood disorders. We discuss its mechanism of action, clinical evidence for its use in depression and bipolar disorder, and its possible benefits for both adults and children. Could this natural compound revolutionize our approach to mood stabilization? Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies Exploring the Evidence of N-Acetyl-Cysteine (NAC) for Mood Disorders

Oct 8, 2024

In this episode, we explore the potential use of probiotics in treating ADHD symptoms in children and adolescents. Could the gut microbiome hold the key to managing this complex neurodevelopmental disorder? We discuss a recent meta-analysis and its implications for future research and clinical practice. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 19 Efficacy of Probiotics in Treating ADHD Symptoms

Oct 3, 2024

In this episode, we explore the challenges and best practices for managing bipolar disorder during pregnancy. We discuss key medications, their risks and benefits, and the importance of individualized treatment plans. How do we balance maternal mental health with fetal safety when treating bipolar disorder in pregnant women? Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Perinatal Treatment of Bipolar Disorder Guiding Principles for Treating Bipolar Disorder During Pregnancy

Sep 28, 2024

In this episode, we explore a recent study challenging the safety concerns surrounding haloperidol use in older patients post-surgery. We discuss its implications for managing delirium and compare it to other antipsychotics. Could haloperidol be the unsung hero in our psychopharmacological arsenal? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 59 Comparative Safety of Oral Antipsychotics for Adverse Events in Adults After Surgery

Sep 23, 2024

In this episode, we explore the use of atypical antipsychotics during pregnancy for women with bipolar disorder. We discuss recent research findings, potential risks, and the delicate balance between managing maternal mental health and fetal safety. How do clinicians approach this challenging clinical decision? Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Perinatal Treatment of Bipolar Disorder Risks of Using Antipsychotics During Pregnancy

Sep 18, 2024

In this episode, we explore the use of risperidone in treating anorexia nervosa in children and adolescents. We discuss a groundbreaking study examining its efficacy and tolerability. Can atypical antipsychotics like risperidone offer hope for young anorexia patients, or are we still searching for effective pharmacological treatments? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: CAP Smart Takes Vol. 18 Efficacy of Risperidone as Treatment for Anorexia Nervosa

Sep 13, 2024

In this episode, we explore the complexities of managing lithium during pregnancy for women with bipolar disorder. How do lithium levels change throughout pregnancy, and what monitoring is necessary? We discuss dosing strategies, fetal monitoring, and postpartum considerations to ensure the best outcomes for both mother and baby. Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Perinatal Treatment of Bipolar Disorder Bipolar Disorder During Pregnancy: Management of Lithium

Sep 8, 2024

In this episode, we explore the revolutionary potential of daridorexant, a new dual orexin receptor antagonist (DORA) for treating chronic insomnia. We discuss its unique mechanism of action, efficacy, and implications for future insomnia treatment. Could this medication be the key to "turning off" wakefulness in stubborn cases of insomnia? Faculty: Carlos H. Schenck, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 58 Use of Daridorexant for the Management of Chronic Insomnia

Sep 3, 2024

In this episode, we explore the risks and benefits of using lithium during pregnancy for women with bipolar disorder. We discuss recent research on cardiac malformations and dose-dependent risks. Is the fear of lithium use in pregnancy justified by the latest evidence? Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Perinatal Treatment of Bipolar Disorder Risks of Using Lithium in Pregnancy

Aug 29, 2024

In this episode, we explore a groundbreaking study on escitalopram's efficacy in treating generalized anxiety disorder in children and adolescents. We discuss its potential as the first FDA-approved medication for youth anxiety. How might this change our approach to pediatric anxiety treatment? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 18 The Role of Escitalopram in Treating Generalized Anxiety Disorder in Youth

Aug 24, 2024

In this episode, we explore psychodynamic psychopharmacology and its role in addressing treatment-resistant cases. We discuss how patient-doctor relationships, transference, and countertransference can impact medication effectiveness. How might your own unconscious biases influence your prescribing decisions? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.75 CME: Psychodynamic Psychopharmacology: From Biomedical Approaches to Patient Relationships Cultivating a Therapeutic Alliance

Aug 19, 2024

In this episode, we explore the therapeutic potential of psychedelic compounds in psychiatry. We discuss their definition, mechanism of action, and potential uses in treating anxiety and depression. How might psychedelics reshape the future of psychopharmacology? Faculty: Sidney LeFay, D.O. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 58 Psychedelics as Transformative Therapeutics

Aug 14, 2024

In this episode, we explore the concept of patient ambivalence in psychopharmacology. How can understanding a patient's conflicting feelings about treatment improve outcomes? We discuss strategies for recognizing and addressing ambivalence, and its impact on medication adherence and effectiveness. Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.75 CME: Psychodynamic Psychopharmacology: From Biomedical Approaches to Patient Relationships Attending the Patient's Ambivalence